Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Core Insights - VolitionRx Limited will host a virtual investor event on February 14, 2025, featuring key management personnel [1] - The event will focus on the Nu.Q® NETs H3.1 biomarker, which shows promise for early detection of mortality and organ dysfunction in sepsis [2] - An update on commercialization efforts through licensing and sales will be provided by the Chief Commercial Officer [3] Company Overview - Volition is a multi-national company dedicated to advancing epigenetics and improving outcomes for patients with life-altering diseases through early detection [7] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers and sepsis-related conditions [8] - Research and development activities are primarily based in Belgium, with additional facilities in the U.S. and London [8] Key Personnel - Dr. Andrew Retter, Chief Medical Officer, has extensive experience in critical care and has published over 50 articles in peer-reviewed journals [4] - Gael Forterre, Chief Commercial Officer, has a strong background in commercialization and investment, previously serving as CEO of Pathify [5][6]